Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by themagicboxon Jul 23, 2022 5:36pm
183 Views
Post# 34845787

RE:Keep this in mind LONGs ...

RE:Keep this in mind LONGs ...Slight correction to your comment: *we have the best in class NSAID* 

Having said that, remember folks, perfection is the enemy of good. We dont have to be the "best", we just have to be better than what already exists. I promise once ATB-346 hits the market, it will be used "chronically" and you'll see NSAID related GI complications disappear. Liver enzyme elevation in less than 10% of the population is fantastic for an NSAID that is this potent on the womac scale. 

“Each year more than 100,000 patients are hospitalized for NSAID-related GI complications alone, with direct costs ranging from $1800 to $8500 per patient per hospitalization. Moreover, it has been reported that 16,500 persons die annually from these complications. In the elderly, the medical costs of adverse GI events associated with NSAID use likely exceed $4 billion per year”  (Fine, 2013) 

And just as an added bonus for the walstreetbet types, deepf*ckingvalue had ATE.V on his radar. 

Ignore the fudsters and trolls. They have no lives and giving them attention gives them energy to keep going. Best to pity them. Enjoy the rest of your weekend folks.
<< Previous
Bullboard Posts
Next >>